Canada · Delayed Price · Currency is CAD BioRem Statistics
Total Valuation
BioRem has a market cap or net worth of CAD 52.76 million. The enterprise value is 44.09 million.
| Market Cap | 52.76M |
| Enterprise Value | 44.09M |
Important Dates
The next estimated earnings date is Friday, May 22, 2026.
| Earnings Date | May 22, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
BioRem has 16.13 million shares outstanding. The number of shares has decreased by -0.40% in one year.
| Current Share Class | 16.13M |
| Shares Outstanding | 16.13M |
| Shares Change (YoY) | -0.40% |
| Shares Change (QoQ) | -10.19% |
| Owned by Insiders (%) | 2.00% |
| Owned by Institutions (%) | n/a |
| Float | 15.81M |
Valuation Ratios
The trailing PE ratio is 12.58 and the forward PE ratio is 10.90.
| PE Ratio | 12.58 |
| Forward PE | 10.90 |
| PS Ratio | 1.25 |
| PB Ratio | 3.53 |
| P/TBV Ratio | 3.53 |
| P/FCF Ratio | 7.26 |
| P/OCF Ratio | 6.91 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 6.26, with an EV/FCF ratio of 6.06.
| EV / Earnings | 9.15 |
| EV / Sales | 1.04 |
| EV / EBITDA | 6.26 |
| EV / EBIT | 6.71 |
| EV / FCF | 6.06 |
Financial Position
The company has a current ratio of 1.85, with a Debt / Equity ratio of 0.19.
| Current Ratio | 1.85 |
| Quick Ratio | 1.62 |
| Debt / Equity | 0.19 |
| Debt / EBITDA | 0.40 |
| Debt / FCF | 0.39 |
| Interest Coverage | 40.59 |
Financial Efficiency
Return on equity (ROE) is 37.70% and return on invested capital (ROIC) is 75.92%.
| Return on Equity (ROE) | 37.70% |
| Return on Assets (ROA) | 13.24% |
| Return on Invested Capital (ROIC) | 75.92% |
| Return on Capital Employed (ROCE) | 38.49% |
| Weighted Average Cost of Capital (WACC) | 8.51% |
| Revenue Per Employee | 1.25M |
| Profits Per Employee | 141,665 |
| Employee Count | 34 |
| Asset Turnover | 1.36 |
| Inventory Turnover | 13.85 |
Taxes
In the past 12 months, BioRem has paid 1.51 million in taxes.
| Income Tax | 1.51M |
| Effective Tax Rate | 23.89% |
Stock Price Statistics
The stock price has increased by +72.43% in the last 52 weeks. The beta is 0.81, so BioRem's price volatility has been lower than the market average.
| Beta (5Y) | 0.81 |
| 52-Week Price Change | +72.43% |
| 50-Day Moving Average | 2.65 |
| 200-Day Moving Average | 2.37 |
| Relative Strength Index (RSI) | 73.07 |
| Average Volume (20 Days) | 54,995 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, BioRem had revenue of CAD 42.36 million and earned 4.82 million in profits. Earnings per share was 0.26.
| Revenue | 42.36M |
| Gross Profit | 12.77M |
| Operating Income | 6.57M |
| Pretax Income | 6.33M |
| Net Income | 4.82M |
| EBITDA | 6.91M |
| EBIT | 6.57M |
| Earnings Per Share (EPS) | 0.26 |
Balance Sheet
The company has 11.50 million in cash and 2.83 million in debt, with a net cash position of 8.67 million or 0.54 per share.
| Cash & Cash Equivalents | 11.50M |
| Total Debt | 2.83M |
| Net Cash | 8.67M |
| Net Cash Per Share | 0.54 |
| Equity (Book Value) | 14.93M |
| Book Value Per Share | 0.93 |
| Working Capital | 14.05M |
Cash Flow
In the last 12 months, operating cash flow was 7.64 million and capital expenditures -367,826, giving a free cash flow of 7.27 million.
| Operating Cash Flow | 7.64M |
| Capital Expenditures | -367,826 |
| Depreciation & Amortization | 334,539 |
| Net Borrowing | -682,438 |
| Free Cash Flow | 7.27M |
| FCF Per Share | 0.45 |
Margins
Gross margin is 30.14%, with operating and profit margins of 15.52% and 11.37%.
| Gross Margin | 30.14% |
| Operating Margin | 15.52% |
| Pretax Margin | 14.94% |
| Profit Margin | 11.37% |
| EBITDA Margin | 16.31% |
| EBIT Margin | 15.52% |
| FCF Margin | 17.17% |
Dividends & Yields
BioRem does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 0.40% |
| Shareholder Yield | 0.40% |
| Earnings Yield | 9.13% |
| FCF Yield | 13.78% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
BioRem has an Altman Z-Score of 3.84 and a Piotroski F-Score of 7.
| Altman Z-Score | 3.84 |
| Piotroski F-Score | 7 |